Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis

被引:56
作者
Fecker, Lothar F.
Geilen, Christoph C.
Tchernev, Georgi
Trefzer, Uwe
Assaf, Chalid
Kurbanov, Bachtier M.
Schwarz, Constanze
Daniel, Peter T.
Eberle, Juergen
机构
[1] Charite Univ Med Berlin, Dept Dermatol & Allergy, Skin Canc Ctr, D-14195 Berlin, Germany
[2] Charite Univ Med Berlin, Dept Hematol, Berlin, Germany
关键词
D O I
10.1038/sj.jid.5700192
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Prognosis of primary melanoma is presently based on morphological parameters, mainly tumor thickness. However, more reliable prognostic markers are needed that allow a better stratification of patients, especially with regard to therapeutic options. Here, a retrospective study was performed on patients with primary superficial-spreading melanoma (SSM, n = 44) or nodular melanoma (n = 16) of 1.5-4mm thickness. Thirty patients had survived the follow-up of 10 years, whereas the other 30 patients developed metastases. Tumor sections were analyzed by immunohistochemistry for the expression of regulators of the cell cycle (p21; retinoblastoma protein (pRb)), of the intrinsic or extrinsic proapoptotic pathways (p53; murine double minute gene 2 protein; tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-R1/DR4; TRAIL-R2/DR5) and of Bcl-2-related proteins (Bcl-2, Mcl-1, Bax, Bak, Bok), which regulate the common mitochondrial apoptotic pathway. In SSM, decrease of Bax and Bak was significantly correlated with a poor prognosis: high Bax was associated with 10-year survival rates of 68%, whereas low Bax resulted in only 26% survival, and high Bak was associated with 10-year survival rates of 62%, whereas low Bak resulted in only 10% survival. Regulators of apoptosis may therefore candidate for independent prognostic markers for primary melanomas. The study underlines the particular role of the mitochondrial apoptosis pathway and of proapoptotic Bcl-2-related proteins for melanoma progression.
引用
收藏
页码:1366 / 1371
页数:6
相关论文
共 30 条
[1]  
Bachmann IM, 2004, INT J ONCOL, V25, P1559
[3]  
CLARK WH, 1969, CANCER RES, V29, P705
[4]   The BCL2 family: Regulators of the cellular life-or-death switch [J].
Cory, S ;
Adams, JM .
NATURE REVIEWS CANCER, 2002, 2 (09) :647-656
[5]   Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes [J].
Dadras, SS ;
Lange-Asschenfeldt, B ;
Velasco, P ;
Nguyen, L ;
Vora, A ;
Muzikansky, A ;
Jahnke, K ;
Hauschild, A ;
Hirakawa, S ;
Mihm, MC ;
Detmar, M .
MODERN PATHOLOGY, 2005, 18 (09) :1232-1242
[6]   Guardians of cell death:: the Bcl-2 family proteins [J].
Daniel, PT ;
Schulze-Osthoff, K ;
Belka, C ;
Güner, D .
PROGRAMMED CELL DEATH, 2003, 39 :73-88
[7]   The kiss of death: promises and failures of death receptors and ligands in cancer therapy [J].
Daniel, PT ;
Wieder, T ;
Sturm, I ;
Schulze-Osthoff, K .
LEUKEMIA, 2001, 15 (07) :1022-1032
[8]   CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants [J].
Eberle, J ;
Fecker, LF ;
Hossini, AM ;
Wieder, T ;
Daniel, PT ;
Orfanos, CE ;
Geilen, CC .
ONCOGENE, 2003, 22 (57) :9131-9141
[9]   Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer staging system: An analysis of the German Central Malignant Melanoma Registry [J].
Eigentler, TK ;
Buettner, PG ;
Leiter, U ;
Garbe, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4376-4383
[10]   Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression [J].
Fecker, LF ;
Geilen, CC ;
Hossini, AM ;
Schwarz, C ;
Fechner, H ;
Bartlett, DL ;
Orfanos, CE ;
Eberle, J .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 124 (01) :221-228